Nemaura Medical

Nemaura Medical, Inc. operates as a holding company. The firm engages in the provision of medical device research. It manufactures and commercializes glucose monitoring system, named sugarBEAT. The sugarBEAT consists of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five minute intervals with the use of a mobile app. The company was founded by Dewan Fazlul Hoque Chowdhury on December 24, 2013 and is headquartered in New York, NY.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Loughborough, England, March 11, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces its submission to G-BA (Gemeinsamer Bundesausschuss) for approval of sugarBEAT®, the Company's non-invasive, daily wear, continuous glucose monitoring device.

Nemaura Medical Announces Submission to German Authorities for Reimbursement of its Glucose Monitoring Device

Loughborough, England, March 10, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces that CEO Faz Chowdhury, Ph.D. will present at Maxim Group's Inaugural Emerging Growth Virtual Conference to be held March 17-18, 2021.

Nemaura Medical to Present at Maxim Group's Inaugural Emerging Growth Virtual Conference

Loughborough, England, March 04, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces the appointment of industry stalwart Alistair Longmuir as an advisor for their global product manufacture strategy.

Nemaura Medical Appoints Industry Veteran Alistair Longmuir as Advisor on Global Product Manufacture Strategy

Nemaura Medical Inc (NASDAQ:NMRD) has reported that it ended its third quarter with $14,959,785 in cash on the books as of December 31, 2020, up from $1,067,663 at the same stage a year earlier. The company also said it has a cash balance of $33 million as of February 15, 2021, after recently receiving a $20 million non-dilutive, non-convertible loan secured by company assets.

Nemaura Medical sees its 3Q cash balance swell to nearly $15M

Loughborough, England, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces financial results for its fiscal third quarter ending December 31, 2020 and provides a corporate update.

Nemaura Medical Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update

Nemaura Medical Inc (NASDAQ:NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has obtained a $20 million non-dilutive, non-convertible loan secured by company assets.  The loan does not include warrants or other equity securities, the company said in a statement Thursday.

Nemaura Medical says it has obtained a $20 million non-dilutive, non-convertible loan

Loughborough, England, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces it has secured a $20 million non-dilutive, non-convertible loan that was secured by Company assets. The loan does not include warrants or other equity securities.

Nemaura Medical Secures $20 Million Non-Dilutive Loan to Accelerate Business Growth

Nemaura Medical (NMRD) stock is on the rise Monday with heavy trading despite a lack of news concerning the medical company. The post NMRD Stock: 8 Things to Know About Biopharma Nemaura Medical as Shares Soar appeared first on InvestorPlace.

NMRD Stock: 8 Things to Know About Biopharma Nemaura Medical as Shares Soar

Nemaura Medical's novel non-invasive continuous glucose monitoring devise is one of the most underrated devices on the market. The lack of attention to this device and the underestimation of the prediabetic market has led the market to chronic undervaluation of NMRD.

Nemaura Medical's SugarBEAT: A Rising Star In Continuous Glucose Monitoring

Loughborough, England, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces the appointment of Thomas Mortensen as head of E.U. commercial operations and marketing.

Nemaura Medical Appoints Thomas Mortensen as Head of E.U. Commercial Operations and Marketing

After nearly a decade of R&D and preparation for commercialization, NMRD is on the cusp of signing its first large customers. Operating leverage should be strong, with only one to two large customers needed for NMRD to break even.

Nemaura Medical: Lowering Glucose Levels Will Increase Share Price

LOUGHBOROUGH, England, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces the official launch of its flagship program, BEAT®diabetes, and the availability of its proprietary non-invasive, daily-wear adhesive glucose monitor, proBEAT™.

Nemaura Medical Launches BEAT®diabetes Program and Its Novel proBEAT™ Non-Invasive, Daily-Wear Adhesive Glucose Monitor

LOUGHBOROUGH, England, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces announces that CEO Dr. Faz Chowdhury will present a corporate overview at the 13th Annual LD Micro Main Event virtual investor conference on Tuesday, December 15 at 8:00 AM PST/11:00 AM EST. The format will be a 10-minute presentation followed by a 10-minute Q&A session with a panel of investors and analysts.

Nemaura Medical to Present at the 13th Annual LD Micro Main Event Virtual Conference

LOUGHBOROUGH, England, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces the re-launch of its corporate website, www.nemauramedical.com, and the website for its flagship program, BEAT™diabetes, www.beatdiabetes.life, which serves as the unofficial launch of the program and allows users to register and learn about participating in an overall health management system to potentially reverse Type 2 diabetes.

Nemaura Medical Launches BEAT™diabetes Program Through New Web Presence and Re-Launches Enhanced Corporate Website

LOUGHBOROUGH, England, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized  lifestyle coaching programs, today announces financial results for the second quarter ended September 30, 2020 and provides a corporate update.

Nemaura Medical Reports Financial Results for Second Quarter of Fiscal Year 2020/21 and Provides Corporate Update

LOUGHBOROUGH, England, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces that it will present on Day 1 of the Virtual Diabetes Technology Meeting 2020 on November 12, 2020 at 2:50 PT. Nemaura's Chief Executive Officer Dr. Faz Chowdhury will give a presentation titled “CGM Usage for the Management and Reversal of Type 2 diabetes.”

Nemaura Medical to Present at Virtual Diabetes Technology Meeting 2020

Clinically proven app  from  Healthimation , LLC ,  to be paired with Company’s  pro BEAT ™  non-invasive CGM  system solution  to offer convenient and effective management of  pre-diabetes and  Type 2  diabetes

Nemaura Medical Licenses Validated Mobile Application to Create Powerful Diabetes Prevention and Management Suite of Products

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces it has appointed Justin Mclarney as Chief Finance Officer, effective September 15, 2020.

Nemaura Medical Appoints Justin Mclarney as Chief Finance Officer

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT™diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced

Nemaura Medical to Provide US proBEAT™ Launch Update at The LD 500 Virtual Conference

Nemaura Medical to Present at The LD 500 Virtual Conference

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT™diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today issued a p

Nemaura Medical Issues Presentation Pertaining to the use of Continuous Glucose Monitoring in COVID-19 Patients

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT™diabetes, a health subscription service designed to help people with diabetes and pre-diabetes to better manage their condition through personalized lifestyle coaching, today provided a business update and on August 14, 2020 released financial results for the quarter ende

Nemaura Medical Reports Results and Provides Business Update for the First Quarter Ended June 30, 2020

Nemaura Medical (NASDAQ: NMRD) shares are trading lower on Tuesday after the company filed for a common stock offering of 1.6 million shares.

Why Nemaura Medical's Stock Is Trading Lower Today

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching, today announced

Nemaura Announces Correction and Pricing of Public Offering

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching, announced that i

News for Nemaura Medical Stock (NMRD)